Publication Name	World Journal of Gastroenterology
Manuscript ID	5816
Country	China

Received	2013-09-27 06:46
Peer-Review Started	2013-09-27 17:31
To Make the First Decision	2013-12-26 10:55
Return for Revision	2014-01-17 10:11
Revised	2014-02-07 21:27
Second Decision	2014-02-20 15:17
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-02-20 16:05
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-04-11 10:16
Publish the Manuscript Online	2014-04-17 13:27

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Topic Highlights
Article Title	Anti-EGFR and anti-VEGF agents: Important targeted therapies of colorectal liver metastases
Manuscript Source	Invited Manuscript
All Author List	Qing-Yang Feng, Ye Wei, Jing-Wen Chen, Wen-Ju Chang, Le-Chi Ye, De-Xiang Zhu and Jian-Min Xu
Funding Agency and Grant Number
Corresponding Author	Jian-Min Xu, MD, PhD, Department of General Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, China. xujmin@aliyun.com
Key Words	Oncology; Colorectal cancer; Liver metastases; Chemotherapy; Targeted therapy
Core Tip	Targeted therapy is becoming standard for patients with colorectal liver metastases, but new findings continue to improve our understanding of these therapies. “New” RAS mutations, rather than the Kirsten rat sarcoma viral oncogene G13D mutation, may be predictive of non-responsiveness to anti-epidermal growth factor receptor therapy. The regimen of cetuximab plus FOLFOX is likely effective, but bevacizumab plus oxaliplatin-based chemotherapy remains controversial. Bevacizumab was suggested to be unsuitable for conversion therapy. Further confirmation is required to demonstrate the effectiveness of targeted therapy as a pre- or postoperative treatment. Combination therapy with more than one targeted agent is not recommended.
Publish Date	2014-04-17 13:27
Citation	Feng QY, Wei Y, Chen JW, Chang WJ, Ye LC, Zhu DX, Xu JM. Anti-EGFR and anti-VEGF agents: Important targeted therapies of colorectal liver metastases. World J Gastroenterol 2014; 20(15): 4263-4275
URL	http://www.wjgnet.com/1007-9327/full/v20/i15/4263.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i15.4263

Full Article (PDF)	WJG-20-4263.pdf
Full Article (Word)	WJG-20-4263.doc
Manuscript File	5816-Review.doc
Answering Reviewers	5816-Answering reviewers.pdf
Copyright License Agreement	5816-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	5816-Language certificate.pdf
Peer-review Report	5816-Peer reviews.pdf
Scientific Editor Work List	5816-Scientific editor work list.doc